[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bipolar-and-related-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bipolar-and-related-disorders":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,82,94,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100054287","an-innovative-master-platform-for-clinical-trials-in-mood-disorders-100054287",false,"NCT06408012","An Innovative Master Platform for Clinical Trials in Mood Disorders","Enabling Neuroscience Research Approaches for Brain, feeLings and Emotions (ENABLE): An Innovative Platform for Clinical Trials in Mood Disorders","ENABLE","Inclusion Criteria\n\nPatients:\n\n1. 16 years of age or older.\n2. Meet criteria for bipolar or depressive disorders as defined by DSM-5.\n3. Fluency in English, sufficient to complete the interviews and self-report questionnaires.\n\nInclusion Criteria\n\nHealthy Comparison (HC) Participants:\n\n1. 16 years of age or older.\n2. No history of psychiatric disorders (according to DSM-5) or significant unstable medical conditions.\n3. Fluency in English, sufficient to complete the interviews and self-report questionnaires.",true,"ALL","16 Years",{"count":21,"type":22},2200,"ESTIMATED","1 Day","OBSERVATIONAL","Mood disorders such as depression and bipolar disorder affect over 350 million people around the world. While several effective treatments exist, it is often difficult to match the right treatment to an individual person. Repeated efforts to find the right treatment contribute to poor functioning, low quality of life, and prolongs the time it takes to get well. Most areas of medicine are able to use 'biomarkers' or clinical tests, blood tests, or imaging to help diagnose and treat illness. The search for biomarkers in mood disorders is advancing, but one roadblock to progress is the lack of large, standardized studies of mood disorders that are needed to accurately identify biomarkers. The aim of the ENABLE platform is to provide the Canadian neuroscience community a standardized way of collecting biomarker data from individuals with a range of mood disorders symptoms. In addition, this 'master clinical trial platform' framework will provide a pool of participants who can be recruited into biomarker-based clinical trials.",[27,28,29],"Mood Disorders","Depressive Disorder","Bipolar and Related Disorders","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2023-10-17",{"date":38,"type":22},"2029-03-31",{"name":40,"class":41},"St. Joseph's Healthcare Hamilton","OTHER",9,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":18,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100631852","implementing-action-based-cognitive-remediation-for-transdiagnostic-cognitive-difficulties-in-a-tertiary-mental-health-hospital-100631852","NCT07506070","Implementing Action-Based Cognitive Remediation for Transdiagnostic Cognitive Difficulties in a Tertiary Mental Health Hospital","Inclusion Criteria:\n\n* Participants must have been given a diagnosis of a psychiatric disorder (such as mood anxiety, psychotic disorders, etc.\n* Participants must have reported subjective cognitive difficulties associated with their psychiatric disorder\n* Participants must be capable of providing informed consent\n* Participants must have the ability to speak and read in either English or French\n* Participants must have no changes to their medication intake (such as starting or stopping medication or changing doses) within the past month before providing consent for participation\n\nExclusion Criteria:\n\n* Participants will be excluded if they are hospitalized at the time of recruitment\n* Participants will be excluded if they have a confirmed diagnosis of an intellectual disability","18 Years","60 Years",{"count":52,"type":22},160,"INTERVENTIONAL",[55],"NA","Psychiatric conditions are each defined by different set of symptoms, however, they often share common characteristics such as impairments in cognitive and social functioning. These impairments can cause significant distress and disrupt daily functioning by preventing individuals from actively participating in school or work, maintaining healthy relationships with others, and engaging in everyday activities independently. The goal of this clinical trial is to examine if action-based cognitive remediation (ABCR) therapy, a type of cognitive training program, works to treat cognitive impairments in participants with psychiatric disorders.\n\nThe main questions it aims to answer are:\n\n* Whether the intervention will improve the thinking skills of participants with different types of psychiatric conditions\n* Whether the intervention will improve social skills and work performance\n* Can this program be easily used in a regular hospital, and do the people who take part in it find it helpful and worth their time\n* Whether the improvements from the intervention last for a long time after the training is over.\n\nResearchers will compare how much the thinking skills of participants change during an 8-week waiting period (where they get no treatment) to how much they change during the 8-week training program to see if the training makes a bigger difference in helping them think and live better.\n\nParticipants will :\n\n* Complete a series of questionnaires on memory, thinking skills, and mental health at the beginning of the study\n* Wait 8 weeks without any intervention or training\n* Complete the series of questionnaires again\n* Complete an 8-week training intervention of ABCR where they will use special computer programs to practice real-life skills and tasks like planning a meal or making an appointment\n* Complete the series of questionnaires and an additional structured interview to assess acceptability and feasibility of the intervention.\n* 3 month later, complete questionnaires for a final time.",[58,59,60,61,29,62,63],"Psychiatric Disorders","Depression - Major Depressive Disorder","Schizophrenia and Other Psychotic Disorders","Anxiety and Mood Disorders","PTSD - Post Traumatic Stress Disorder","Autism Spectrum Disorder",[65,66,67,58,68,69,70,71],"Transdiagnostic","Action-Based Cognitive Remediation","Cognitive Remediation Therapy","Cognitive Impairments","Cognitive Deficits","Neurocognition","Social Cognition","NOT_YET_RECRUITING","2026-04-15",{"date":75,"type":34},"2026-04-20",{"date":77,"type":22},"2026-05-01",{"date":79,"type":22},"2031-05-01",{"name":81,"class":41},"The Royal Ottawa Mental Health Centre",{"id":83,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":84,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":86,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":93,"locationsCount":42},"100547441",{"count":85,"type":22},900,[27,28,29],"2026-01-20",{"date":89,"type":34},"2026-01-22",{"date":36,"type":34},{"date":92,"type":22},"2026-03-31",{"name":40,"class":41},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":18,"minAge":49,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":53,"phases":104,"briefSummary":105,"conditions":106,"keywords":116,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100573643","ketogenic-metabolic-therapy-in-schizophrenia-bipolar-disorder-major-depressive-disorder-deep-omic-profiling-100573643","NCT06748950","Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling","A Randomized Controlled Trial of a Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling","Inclusion Criteria:\n\n1. diagnosed with bipolar disorder (BD), major depressive disorder (MDD), and or schizophrenia\n\n   1. For individuals diagnosed with bipolar disorder (BD):\n\n      * Meet DSM V criteria for BD (any subtype)\n      * Not mild\n      * \\>40 on BPRS\n      * clinically stable (with no hospitalization for past 3 months)\n   2. For individuals diagnosed with major depressive disorder (MDD):\n\n      * Not mild\n      * PHQ-9 \\> 10\n      * clinically stable (with no hospitalization for past 3 months)\n   3. For individuals diagnosed with schizophrenia:\n\n      * Meet DSM V criteria for schizophrenia (any subtype)\n      * Not mild\n      * \\>40 on BPRS\n      * clinically stable (with no hospitalization for past 3 months)\n2. Participants may currently be on a stable and adequate dose of SSRI antidepressant therapy or other psychiatric medication. Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, or trazodone) will be allowed if the therapy has been stable for at least four weeks prior to screening and if it is expected to remain stable. Participants may be switched from other classes of medication to another medication class by their psychiatrist or primary care doctor, but need to be stable enough to enroll and adhere to study procedures.\n3. willing and able to give informed consent for participation in English.\n4. live within the United States.\n\n   \\--------------------------------------------------------------------------------\n\nExclusion Criteria:\n\n1. has started the ketogenic diet or was in ketosis within 3 months of wanting to enroll\n2. pregnant or nursing\n3. insulin dependent\n4. comorbidity of developmental delay\n5. in a current severe mood or psychotic state when entering the study that would prohibit compliance with study visits or dietary programs.\n6. any one who has been hospitalized or taken clozapine at doses above 550mg over the past 3 months\n7. inability to complete baseline measurements\n8. severe renal or hepatic insufficiency\n9. cardiovascular dysfunction, including diagnosis of:\n\n   * Congestive heart failure\n   * Angina\n   * Arrhythmias\n   * Cardiomyopathy\n   * Valvular heart disease\n10. active substance abuse with illicit drugs or alcohol and\u002For current diagnosis of a Substance Use Disorder (Abuse or Dependence, as defined by DSM-IV-TR), with the exception of nicotine or cannabis dependence\n11. active suicidal and considered at significant risk for suicide during course of study\n12. participation in any clinical trial- within the past month or concurrent to study participation- with an investigational drug\u002Fdevice and\u002For intervention that may interfere with study participation\u002Fevaluation of results\n13. mild BPRS at screening or baseline visits\n14. history of TBI\n15. any other medical condition that may make diet intervention dangerous as determined by the study medical team (e.g. anorexia nervosa) or assessed by study team to have insufficient control over their food intake to adhere to study diets.\n16. any medical condition that physicians or the PI believe would interfere with study participation or evaluation of results\n17. history of familial hypercholesterolemia","80 Years",{"count":103,"type":22},120,[55],"The goal of this randomized clinical trial is to be adequately powered to evaluate the effect of ketogenic metabolic therapy on the quality of life in serious mental illness, schizophrenia, bipolar disorder, major depressive disorder.",[107,108,109,29,110,111,112,113,114,115],"Schizophrenia","Schizophrenia and Related Disorders","Bipolar Disorder","Major Depressive Disorder","Major Depression Severe","Ketogenic Dieting","Ketosis","Metabolic Disease","Metabolic Syndrome",[117,118,119,120],"Mental Illness","Multiomics","Multi-omics","Omics Profiling","2025-05-13",{"date":123,"type":34},"2025-05-16",{"date":125,"type":22},"2025-07",{"date":127,"type":22},"2028-07",{"name":129,"class":41},"Stanford University",1,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":18,"minAge":49,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":53,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":130},"100555158","a-mental-health-services-engagement-program-for-racial-and-ethnic-minority-young-adults-100555158","NCT06508450","A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults","Adapting and Testing A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults","Inclusion Criteria:\n\n* Aged 18-34\n* From groups other than non-Hispanic White\n* Enrolled in services at the partnering clinic site\n\nExclusion Criteria:\n\n* Cognitive impairments (i.e., young adult cannot understand consent process)\n* Unable to comprehend and speak English","34 Years",{"count":140,"type":22},80,[55],"Researchers aim to test a brief culturally-responsive young adult orientation program for community mental health services. They will conduct a 24-month randomized trial with 80 young adults from racial and ethnic minority groups in a community-based mental health clinic.",[144,29,28],"Psychosis","2025-03-10",{"date":147,"type":34},"2025-03-13",{"date":149,"type":34},"2024-12-18",{"date":151,"type":22},"2027-03",{"name":153,"class":41},"New York University"]